These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 32541316)

  • 1. Novel therapeutic options for alveolar soft part sarcoma: antiangiogenic therapy, immunotherapy and beyond.
    Brahmi M; Vanacker H; Dufresne A
    Curr Opin Oncol; 2020 Jul; 32(4):295-300. PubMed ID: 32541316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma: A Review.
    Paoluzzi L; Maki RG
    JAMA Oncol; 2019 Feb; 5(2):254-260. PubMed ID: 30347044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain Metastases and Place of Antiangiogenic Therapies in Alveolar Soft Part Sarcoma: A Retrospective Analysis of the French Sarcoma Group.
    Malouf GG; Beinse G; Adam J; Mir O; Chamseddine AN; Terrier P; Honore C; Spano JP; Italiano A; Kurtz JE; Coindre JM; Blay JY; Le Cesne A
    Oncologist; 2019 Jul; 24(7):980-988. PubMed ID: 30626710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma.
    Reis H; Hager T; Wohlschlaeger J; Bauer S; Katenkamp K; Katenkamp D; Baba HA
    Hum Pathol; 2013 Oct; 44(10):2266-74. PubMed ID: 23871289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 "CREATE" Trial.
    Lee CJ; Modave E; Boeckx B; Kasper B; Aamdal S; Leahy MG; Rutkowski P; Bauer S; Debiec-Rychter M; Sciot R; Lambrechts D; Wozniak A; Schöffski P
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02).
    Xie L; Liang X; Xu J; Sun X; Liu K; Sun K; Li Y; Tang X; Li X; Zhan X; Niu X; Guo W
    BMC Cancer; 2023 Sep; 23(1):868. PubMed ID: 37715133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A durable complete response to immunotherapy in a patient with metastatic alveolar soft part sarcoma.
    Mariuk-Jarema A; Koseła-Paterczyk H; Rogala P; Klimczak A; Wągrodzki M; Maksymiuk B; Rutkowski P
    Tumori; 2020 Dec; 106(6):NP9-NP13. PubMed ID: 32567515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to Immune Checkpoint Inhibition in Two Patients with Alveolar Soft-Part Sarcoma.
    Lewin J; Davidson S; Anderson ND; Lau BY; Kelly J; Tabori U; Salah S; Butler MO; Aung KL; Shlien A; Dickson BC; Abdul Razak AR
    Cancer Immunol Res; 2018 Sep; 6(9):1001-1007. PubMed ID: 30018044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitors.
    Hui E
    J Cell Biol; 2019 Mar; 218(3):740-741. PubMed ID: 30760493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Combinatorial Implications and Theranostics of Immunotherapy in the Impediment of Alveolar Soft Part Sarcoma.
    Yang Y; Beeraka NM; Liu J; Zuo X; Wang X; Li T; Fan R
    Curr Pharm Des; 2022; 28(41):3404-3412. PubMed ID: 36154597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Landscape in Alveolar Soft Part Sarcoma: Implications for Molecular Targeted Therapy.
    Soheilifar MH; Taheri RA; Zolfaghari Emameh R; Moshtaghian A; Kooshki H; Motie MR
    Biomed Pharmacother; 2018 Jul; 103():889-896. PubMed ID: 29710505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in treatment of alveolar soft part sarcoma: an updated review.
    Fujiwara T; Kunisada T; Nakata E; Nishida K; Yanai H; Nakamura T; Tanaka K; Ozaki T
    Jpn J Clin Oncol; 2023 Nov; 53(11):1009-1018. PubMed ID: 37626447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.
    Chang X; Lu X; Guo J; Teng GJ
    Cancer Treat Rev; 2019 Mar; 74():49-60. PubMed ID: 30831375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial.
    Judson I; Morden JP; Kilburn L; Leahy M; Benson C; Bhadri V; Campbell-Hewson Q; Cubedo R; Dangoor A; Fox L; Hennig I; Jarman K; Joubert W; Kernaghan S; López Pousa A; McNeil C; Seddon B; Snowdon C; Tattersall M; Toms C; Martinez Trufero J; Bliss JM
    Lancet Oncol; 2019 Jul; 20(7):1023-1034. PubMed ID: 31160249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical autoimmune adverse effects with checkpoint blockade therapies.
    Friedman CF; Snyder A
    Ann Oncol; 2017 Feb; 28(2):206-207. PubMed ID: 27993802
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of immune checkpoint blockade for brain metastases.
    Harary M; Reardon DA; Iorgulescu JB
    CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898
    [No Abstract]   [Full Text] [Related]  

  • 17. Emerging role of checkpoint inhibition in localized bladder cancer.
    Singh P; Black P
    Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma.
    Kim M; Kim TM; Keam B; Kim YJ; Paeng JC; Moon KC; Kim DW; Heo DS
    Oncologist; 2019 Jan; 24(1):20-e29. PubMed ID: 30254189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment and characterization of NCC-ASPS2-C1: a novel patient-derived cell line of alveolar soft part sarcoma.
    Osaki J; Noguchi R; Yanagihara K; Ono T; Adachi Y; Iwata S; Toda Y; Sekita T; Kobayashi E; Kojima N; Yoshida A; Kawai A; Kondo T
    Hum Cell; 2024 May; 37(3):865-873. PubMed ID: 38478355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies.
    Groisberg R; Roszik J; Conley AP; Lazar AJ; Portal DE; Hong DS; Naing A; Herzog CE; Somaiah N; Zarzour MA; Patel S; Brown RE; Subbiah V
    Mol Cancer Ther; 2020 May; 19(5):1165-1172. PubMed ID: 32127467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.